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 Coffee is one of the most consumed beverages in the world and it has been reported 
to be associated with the risk of cardiovascular disease. Venous Thromboembolism (VTE) is a 
major public health burden, although its association to dietary habits including coffee 
consumption is still underinvestigated. The aim of this thesis was to investigate the 
association between daily coffee intake and the risk of incident VTE, as well as recurrence 
and all-cause mortality after a first VTE event. 
 The study included 30,236 participants aged 25-97 from the fourth (1994-95), fifth 
(2001-02) and sixth (2007-08) surveys of the Tromsø study. Information about daily coffee 
consumption was obtained from questionnaires at the time of enrollment and updated at 
each of the subsequent surveys. All cases of incident VTE, recurrent VTE and death were 
registered during the follow-up period (end of follow up: 31st Dec 2012).  
 A total of 491 incident VTEs occurred during 312,688 person-years (overall IR 1.57, 
95% CI 1.44-1.72). Consuming at least one cup of coffee per day was inversely associated 
with the risk of incident VTE (hazard ratio (HR) 0.63, 95% CI 0.44-0.89) and the risk estimates 
were particularly strong for moderate coffee consumers (3-4 cups: HR 0.58, 95% CI 0.39-
0.84, 5-6 cups: HR 0.59, 95% CI 0.4-0.88) compared to coffee abstainers. Among 491 VTE 
cases, 76 experienced recurrent VTE (recurrent rate: 35.0, 95% CI 28.0-43.8) and 240 died 
(mortality rate: 99.1 95% CI, 79.4-115.8) during the mean follow-up of 4.9 years. Coffee 
drinking was associated with a 66% reduced risk of recurrence (HR 0.34, 95% CI 0.17-0.67) 
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and 18 % lower risk of death (HR 0.82, 95% CI 0.50-1.34). The inverse association persisted 
for all coffee consumption categories. 
 In conclusion, coffee drinking was inversely associated with the risk of incident VTE, 
recurrence and death. A possible U-shape association was revealed, indicating that 
moderate coffee intake might reduce the risk of VTE, recurrence event and death. However, 
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1.1 Venous Thromboembolism (VTE) 
 
Venous thromboembolism (VTE) is a collective 
term for deep vein thrombosis (DVT) and 
pulmonary embolism (PE). Blood clots occurring 
in the deep veins, most commonly in the lower 
limbs are called DVT. PE occurs when a part of 
the blood clot breaks off, is transported in the 
circulation system and obstructs the lung 
arteries, resulting in interruption of blood flow 
to the lung (Figure 1)  [1]. The typical symptoms 
of DVT are leg pain, swelling, itchiness, and 
dropsy or eczema in severe cases [2], while 
symptoms for PE are respiratory distress, 




The mechanism of haemostasis is vital for survival in case of vascular injury. In the event of 
blood vessel injury, endothelial cells signal the platelets in the blood vessels to form a 
platelet plug at the site of vessel injury [4]. This process is called primary haemostasis. Once 
the platelet aggregation completes, the coagulation cascade is triggered by exposure to 
tissue factor/thromboplastin in the sub-endothelial space to create fibrin from fibrinogen [1, 
Figure 1: Venous thromboembolism (VTE) 
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4, 5]. Fibrin generated from the coagulation cascade links to the plug and stabilizes the 
platelet clot. This process is called secondary haemostasis [1, 4]. The clots formed through 
primary and secondary haemostasis prevent blood from flowing out of the blood vessels, 
allowing the vessel injury to heal. However, excessive haemostatic activity in off-target 
places leads to thrombus formation and thromboembolic diseases. Venous thrombi often 
occur in venous valvular sinuses where blood is especially vulnerable to hypoxia and 
hemoglobin desaturation (Figure 2) [6]. In 
contrast to platelet-rich white thrombi which 
occur in arteries where shear stress is high, 
thrombi which form in veins where shear stress is 
low are referred to as red thrombi due to their 





VTE is the third most common cardiovascular disease in the Western world [9, 10], and 
represents a major public health burden. The  incidence rate of VTE is 1-2 per 1,000 person-
years in the adult population, [10-13],  thus corresponding to an estimated total number of 
1.1 million VTE events each year in the European Union (EU) [14].  The incidence rate of DVT 
in the general population is 0.5-1.2 per 1,000 person-years [12, 15], while the incidence rate 
of PE with or without concurrent DVT is 0.3-0.8 per 1000 person-years [13]. The burden of 
VTE might additionally be slightly underestimated due to asymptomatic cases and sudden 
deaths caused by undiagnosed PE [14].  
Figure 2: Venous thrombi formation 
Thrombi most often originate in the venous valve 
pockets characterized by vortex flow and 
hypoxia. The mechanisms that leads to initiation 
of thrombus formation here remains unsettled. 
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Most of the fatal cases in VTE are associated with PE. The short-term mortality rate 
(at 30 days) after the acute onset of PE ranges from 3 to 11% [10, 12], though some studies 
reported increased long-term morality rate (>3 months from onset). An Australian registry 
showed 31.5% cumulative mortality rate after 5 years from an acute PE event, which was 2.5 
times higher compared to the age-and sex- matched general population mortality rate [16]. 
The case-fatality rate was especially high among patients with cancer–related thrombosis 
(25%) [17]. Patients with a first DVT or PE often experience one or more recurrences [10]. 
The recurrence rate after one year from the first VTE is about 7-13% [2, 17-19], and the rate 
is higher among patients with idiopathic VTE [20, 21].  
Pulmonary hypertension and post-thrombotic syndrome (PTS) are two chronic 
complications that can emerge after an VTE event. Two to four percent of the patients 
develop chronic pulmonary hypertension after acute PE, and the condition contributes 
largely to the elevated long-term mortality rate [10]. PTS is a chronic condition that may 
evolve after a DVT. The symptoms include pain, heaviness, and swelling in the limbs and 
lipodermatosclerosis in severe cases [2]. PTS occur in up to 50% of the patients who 
experienced DVT [2, 22], and 5-10% of the patients who had symptomatic DVT can develop 
severe PTS [23]. Advanced age, unprovoked VTE and poorly controlled anticoagulation 
therapy after the incident are strong risk factors for PTS [2, 22]. 
1.4 General Risk Factors and Triggers of VTE 
There are three notable contributors to VTE according to Rudolph Virchow; (i) blood flow 
stasis, (ii) blood composition and (iii) injury in the blood vessel wall [24]. Most risk factors for 
VTE fall into the first two categories (stasis and hypercoagulability) although recent studies 
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have suggested that inflammatory response at the level of the vein wall also is involved in 
thrombogenesis [4]. Known risk factors for VTE include advanced age, obesity, use of 
contraceptive pills, pregnancy, cancer and institutionalization [25, 26]. The risk factors can 
be classified into two categories; hereditary and non-hereditary factors. Among the non-
hereditary factors, there are conditions that last for short periods of time and trigger VTE 
(provoking factors), and chronic factors which persist for a long time (clinical risk factors). 
VTE is a multifactorial disease, therefore co-existence of multiple factors significantly 
increases the risk of developing VTE [27, 28].  For example, a synergistic effect was 
highlighted in a study when carriers of Leiden mutation taking oral contraceptives had a 35-
fold higher risk of VTE compared with non-carriers, which was higher than the sum of risk 
estimations by each risk factor (taking oral contraceptives: Relative Risk (RR) = 3.7, Factor V 
Leiden: RR = 6.9)  [27].  
 
Hereditary risk factors 
 
Recently the significance of genetic factors, especially coagulation abnormality has been 
discovered and initiatively researched [27-29]. A meta-analysis involving 126,525 cases and 
184,068 controls revealed that factor V (G1691A, A4070G), Prothrombin G20210A and 
Plasminogen-activator inhibitor I were significantly associated with VTE in the Caucasian 
population [30]. Factor V Leiden is responsible for activated protein C resistance [31] while 
the Factor II G20210A mutation is associated with exceeding plasma prothrombin 
concentration [28]. The risk of VTE increases by three to eight times for carriers of Factor V 
Leiden [32], and the mutation is found in 1-15% of the Caucasian population and in 10-50% 
of VTE patients [27, 32]. Deficiencies of protein C, protein S and antithrombin are also strong 
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genetic risk factors. The risk of VTE increases by approximately 10-fold for carriers of protein 
C or protein S deficiencies, and 20-fold for antithrombin deficient subjects [27, 31, 33]. Yet, 
the prevalence is rare compared to Factor V Leiden (0.02-0.4% among the healthy 
population) [31].  ABO blood group is associated with the levels of von Willebrand factor 
(vWF) and factor VIII (FVIII). Several studies have revealed that subjects with non-O blood 
type have an about two times higher risk of VTE compared to those with blood type O [34-
37]. Elevated concentrations of FVIII (>150 IU per deciliter) are also partly due to heredity 
[38], and are reported to increase the risk of first and recurrent VTE by 5-fold and 7-fold, 
respectively [39, 40].  
 
Non-hereditary risk factors 
 
Advanced age is a significant risk factor of VTE. VTE occurs in 1 per 10,000 in the young 
population (<40) while the incidence in the elderly population (>80) is 50-80 per 10,000 [41-
43]. The frequency of PE is especially high in the elderly, as it increases from 12 to 70 per 
10,000 as age increases from 65-69 to over 85 years old [41]. Therefore morbidity and case 
fatality rate are high among the elderly [43]. The reasons for the high incidence rate in the 
elderly are still unclear, although accumulation of multiple risk factors and biological change 
due to aging might play an important part. 
Obesity, defined as BMI ≥30 is another clinical risk factor for VTE [9, 44-46]. The 
relative risk of VTE in obese patients was 2.51 (95% confidence interval (CI), 2.49-2.51) 
compared to non-obese patients in the data from National Hospital Discharge Survey (NHDS) 
[45]. Also obese patients had a 60% increased risk of recurrent VTE compared to non-obese 
patients (HR 1.6, 95% CI 1.1-2.4) [44].  
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The use of contraceptive pills, estrogen replacement therapy, pregnancy and the 
postpartum period are all associated with increased risk of VTE in females. The use of 
contraceptive pills increases the risk of developing VTE by two to four times [47-50], 
especially for contraceptives which contain a high dosage of estrogen (≥50 µg) [49]. Due to 
hemostatic changes during pregnancy [51], pregnant women have a four to five times higher 
risk of VTE compared  to non-pregnant women [52-54] and a 22-fold increased risk of VTE 
was revealed during the first six weeks after delivery (the postpartum period) [54]. 
Chronic diseases such as congestive heart failure, chronic kidney disease, and chronic 
inflammatory diseases are also known clinical risk factors of VTE. A case-control study 
revealed a 2.6-fold increase in risk of VTE for patients with congestive heart failure [55]. End-
stage chronic kidney disease was shown to be associated with 2.3-fold higher risk of VTE 
compared to the general population [56]. Also, patients with chronic inflammatory disease 
had 3.5 times greater risk of developing VTE compared to the controls, and the risk was 
particularly high during flare-up periods (HR = 8.4) [57]. 
Cancer is a major risk factor for VTE, associated with a four to seven times higher risk 
of VTE compared to non-cancer subjects [58-60]. Malignant disorders are associated with a 
hypercoagulable state, and often show abnormalities in coagulation tests [61]. The highest 
risk of VTE was found among patients with pancreas, brain, stomach and lung cancer [59, 
60]. A population based nested case-control study revealed that almost one fifth of all VTE 






Triggers of VTE 
 
Provoking factors are transient conditions that trigger VTE, and often those are more 
strongly associated with the risk of VTE compared to chronic risk factors [63]. For example, 
surgery and trauma are well-known triggers of VTE [26, 63]. The risk of asymptomatic VTE 
increased 21 times after surgery and 12 times after trauma in a nested case-control study 
(odds ratio (OR) 21.7 and 12.7 respectively) [63]. Furthermore, the association between 
immobilization and the risk of VTE is well established [26, 63, 64]. For example, in stroke 
patients with hemiplegia, 60% developed DVT in the paralyzed leg while only 7% developed 
it in the other leg [65]. Bed rest for more than three days is also associated with higher risk 
of VTE. An early study found VTE at autopsy in 15% of the patients who were on bed rest for 
more than three days before death [66]. The percentage rose to 80% for those who were in 
bed for 1-2 weeks before death [66]. Travel by air, car, bus or train for more than four hours 
increased the risk of VTE by 2-fold compared to non-travelers [67]. Also a recent case-
control study reported that work-related seated immobility (minimum two hours of seating 
continuously for at least ten hours during a 24-hour period) increased the risk of VTE almost 
3-fold (OR 2.8) [68]. Acute medical conditions and institutionalization also contribute to 
increased risk of VTE since the patients are exposed to multiple risk factors such as surgery, 
immobility, infection and cancer [62, 69]. A retrospective review of a population-based 
cohort revealed a more than 100 times higher risk of VTE among hospitalized patients 







Despite all the known risk factors, 30-50% of VTE cases occur without any predisposing 
factor(s) [13, 33]. These events are classified as unprovoked VTE and this classification has 
clinical importance since the five-year recurrence rate in patients with unprovoked VTE is 2-
10 times higher than for those who had provoked VTE. Extended anticoagulation treatment 
is recommended for patients with unprovoked VTE [70]. Further research is vital in order to 
elucidate new risk factors and triggers of VTE, in order to prevent future events and reduce 
the public health burden caused by VTE. 
 
1.5 Lifestyle Factors and VTE 
 
Although a number of studies examined lifestyle factors such as smoking, physical activity, 
dietary habits and alcohol consumption in relation to the risk of VTE, the findings are 
diverse. Cigarette smoking is an independent risk factor of arterial cardiovascular diseases 
[9, 71], but the association to the risk of VTE is still debatable. A systematic review with 21 
observational studies revealed a 1.2-fold increased risk of VTE for current smokers compared 
to never smokers, and the association followed a dose-response pattern [72]. Some studies 
demonstrated increased risk of VTE only among heavy smokers [73-75] while many revealed 
no association between cigarette smoking and VTE [9, 73, 76, 77], particularly when analysis 
was restricted to non-cancer patients or intermediate development of cancer was taken into 
account [73].  
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  Muscle activity is known to decrease venous pressure and increase blood flow [78, 
79] which could lead to a decrease in VTE. Yet, the findings of studies that investigated the 
relation between physical activity and VTE are not consistent. A large cohort study in 
Sweden with 40,000 female participants revealed a 50% decreased risk of VTE among 
women who engaged in regular physical activity [74]. On the other hand, the Physician’s 
Health Study in the U.S. observed 10% increase in the risk of VTE, if participants increased 
frequency of physical exercise [9]. A prospective study investigating the cardiovascular risk 
factors in relation to VTE revealed no association between physical inactivity and the risk of 
VTE [77]. 
Diet and alcohol consumption might also have an effect on VTE risk. The Longitudinal 
Investigation of Thromboembolism Etiology (LITE) discovered a lower risk of VTE for 
participants who consumed more than four servings of fruit and vegetables per week (HR = 
0.47) and ate fish one or more times a week (HR = 0.58) [80]. Yet, not all papers confirmed 
the association between fish intake and the risk of VTE [81, 82]. Moderate alcohol 
consumption was reported to be beneficial against VTE in several papers [74, 81, 83], while 
some yielded no association [9, 84]. 
 
1.6 Coffee Consumption and Disease Risk 
 
Coffee is one of the most popular beverages worldwide and therefore its association to 
health has gained considerable attention. Inverse associations have been reported between 
coffee consumption and several diseases like diabetes type II [85], Parkinson’s disease [86, 
18 
87], Alzheimer’s disease [88] and some types of cancer [89, 90]. Moreover some reports 
indicated that coffee intake was inversely associated with overall mortality [91, 92].  
There were diverse results reported for the associations between coffee intake and 
cardiovascular diseases. Recently, a large German prospective cohort study revealed no 
association between coffee intake and myocardial infarction (MI) or stroke [93] while meta-
analysis of 21 cohort studies showed a lower risk of coronary heart disease for moderate 
coffee drinkers (1-4 cups per day) [94]. Most studies which assessed the risk association 
between coffee intake and stroke found a decreased risk of fatal and nonfatal stroke for 
coffee consumers [95-97]. Several studies were conducted on coffee consumption and heart 
failure, and the most recent meta-analysis showed a significant J-shaped association 
between coffee consumption and the risk of heart failure [98].  
1.7 Coffee Consumption and VTE 
The association between coffee consumption and the risk of VTE has not been extensively 
studied compared to other cardiovascular diseases. Currently, three observational studies 
[81, 99, 100], and one meta-analysis [101] investigating the relation between coffee 
consumption and the risk of developing incident VTE have been published. In the Iowa 
Women’s Health Study (IWHS), 37,393 women aged 55-69 years were followed for more 
than 19 years and 1,950 VTE events occurred [81]. The study revealed an inverse association 
between moderate coffee consumption and the risk of incident VTE, when the model was 
adjusted for age, energy intake, education, smoking status and physical activity (28 to <42 
servings per week, HR 0.85, 95% CI 0.71-1.01). However, the association was attenuated 
when BMI and diabetes were added to the analytical model (HR 0.88, 95% CI 0.74-1.05) [81]. 
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Enga et al. investigated the association between coffee intake and the risk of VTE 
using the fourth survey of the Tromsø study, a prospective cohort study of the inhabitants of 
the municipality of Tromsø, Norway. Among 26,755 participants, 462 developed VTE during 
13 years of follow-up. The subjects who consumed 3-4 cups of coffee per day had a 30% 
lower risk of VTE (HR 0.70, 95% CI 0.48-1.02), and the subjects who consumed 5-6 cups per 
day had a 33% lower risk of VTE, compared to coffee abstainers (HR 0.67, 95% CI 0.45-0.97) 
[99]. The risk estimates weakened for excessive coffee drinkers (>6 cups per day), indicating 
a possible U-shaped association.  
Findings from a large case-control study, the Multiple Environmental and Genetic 
Assessment of risk factors for venous thrombosis (MEGA) study, are in line with the above 
studies. The study included 1,803 VTE cases matched with partner controls with the 
information of coffee drinking habits and risk of VTE obtained from the anticoagulation 
clinics or questionnaires. Regardless of the amount of coffee consumed per day, the daily 
coffee consumption was correlated with a 25% decreased risk of VTE (OR 0.75, 95% CI 0.55-
1.04) compared to the coffee abstainers [100].  
A meta-analysis that pooled all the three studies described above (inter-study 
heterogeneity: 78%, P<0.001) indicated a pooled RR of 0.97 (95% CI 0.88-1.08) for coffee 
consumers against coffee abstainers. Consuming 1-4 cups per day yielded a RR of 1.11, (95% 
CI 1.0-1.22), however, a significant inverse association was revealed for the group with ≥5 
cups of coffee intake per day (RR 0.75, 95% CI, 0.67-0.85) compared to the participants who 




1.8 Regression Dilution Bias and Time-Varying Analysis 
 
The risk factors in a traditional cohort study are usually measured at the time of the study 
enrollment. However, the status of the exposure might change over time especially when 
the study has a long follow-up period (called time-varying risk factors) [102]. Such 
unpredictable fluctuation of the exposure variables can occur by random measurement 
error, such as imprecise measurement methods or true biological variability [103], or change 
of contexts of the study subjects during the follow-up period. For example, if a study 
participant changes their coffee consumption habit during the study period, the subject will 
be misclassified from the day he/she changed the habit. The transient fluctuations and/or 
true change of exposure occurring during follow-up period could then bias the regression 
slope towards null, resulting in an underestimation of the true association between risk 
factors and outcome [104]. The phenomenon is known as attenuation or regression dilution 
bias [103] and could become a major limitation in conventional prospective cohort studies 
with long follow-up periods. When serial measurements of the exposure variables are 
available in a study, time-varying analysis can be used to correct for the regression dilution 
bias. In time-varying analysis, the follow-up time of each participant is divided into separate 
time-windows. Hazard ratios (HRs) are obtained for each time-window separately by Cox 
analysis, and then, a weighted average of all HRs is calculated (Figure 3) [102]. Since coffee 
consumption habits may vary over time and could influence the risk estimation of the 
outcome, time-varying analysis could be a useful method to overcome the possible 
regression dilution bias.  
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Figure 3: Time-varying Analysis (example)
The previous study by Enga et al had a median follow-up time of 12.5 years, and the 
coffee consumption habits were only measured once at the time of study enrollment [99]. 
For that reason, there is a possibility that the study was affected by the regression dilution 
bias, and thus, the association between coffee and VTE could potentially be stronger than 
estimated in their study. The present study uses a time-varying analysis with repeated 
measurements of the coffee consumption variable to increase the accuracy of the risk 
estimation between coffee intake and VTE. 
Tromsø 4 Tromsø 5 Tromsø 6 

















2.1 Research Problem and Aims 
 
All three previous investigations have reported an inverse association between coffee intake 
and the risk of incident VTE [81, 99, 100]. However, the effect of regression dilution has not 
been addressed in two of the cohort studies. No previous study has investigated the 
association between coffee consumption and risk of recurrent VTE and all-cause mortality 
after VTE. Therefore, the aims of the present study were: 
1) To investigate the association between coffee consumption and the risk of 
incident VTE by using a time-varying analysis to minimize regression dilution bias 
2) To investigate the association between coffee consumption and risk of 







3.1 Study Population 
The study population was recruited from the fourth (1994-1995), fifth (2001-2002) and sixth 
(2007-2008) surveys of the Tromsø study. The Tromsø study is a single centered, population-
based cohort study initially aimed at investigating the reason for high mortality rate due to 
cardiovascular incidences in the Tromsø region. Seven surveys have been conducted until 
the present; in 1974, 1979-1980, 1986-1987, 1994-1995, 2001-2002, 2007-2008 and 2015-
2016. In total, 53,731 residents of the Tromsø municipality were invited and more than 
45,000 unique individuals participated in at least one of the surveys [105]. The Department 
of Community Medicine (ISM) is administrating the study in association with the University 
Hospital of Northern Norway (UNN), the Norwegian Institute of Public Health and the 
Tromsø City Council. 
The fourth Tromsø study invited men and women aged over 25 years for a first 
examination (n=27,158, 77% attendance rate). Then, men aged 55-74, women aged 50-74 
and a small subgroup of residents in different age groups were invited for the extensive 
second examination (n=7,965). The participants of the second examination in Tromsø 4 and 
parts of the inhabitants from particular age groups were invited to Tromsø 5 (n=8,130, 79% 
attendance rate) and Tromsø 6 (n=12,984, 66% attendance rate). In total, 30,586 unique 
individuals attended one or more surveys. Participants who had a VTE event prior to the 
study enrollment (n=78), who did not answer the questionnaires regarding coffee 
consumption in any of the surveys (n=54), who did not give consent to the study (n=181), or 
who moved before the screening (n=37) were excluded from the study analysis. In total, 
30,236 subjects were included in the present study and followed until 31st December 2012 
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(Figure 4). Coffee consumption habits and confounding factors were measured repeatedly 
and updated at each survey. All participants gave written informed consent and the study 
was approved by the Regional Committee of Medical Health Research Ethics North Norway. 
Recruited from Tromsø 4 (1994-1995), Tromsø 5 (2001-2002), and Tromsø 6 (2007-2008).  
Figure 4: Study population
3.2 Measurements 
The information of baseline characteristics was collected at each survey using 
questionnaires, physical examination and blood sampling. Self-administered questionnaires 
covering a wide range of lifestyle aspects, dietary habits, diseases and symptoms were 
completed on the date of inclusion. The question regarding coffee consumption in the 
Tromsø 4 questionnaires was “How many cups of coffee do you usually drink daily?” with 
the categories of “coarsely ground coffee for brewing” or “other coffee”. In the Tromsø 5 
and 6 questionnaires, the categories for the same question were “filtered coffee”, “boiled 
coffee/coarsely ground coffee for brewing” or “other types of coffee”. The answers for each 
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category were combined into a single variable; “total coffee consumption” and categorized 
into “non-coffee drinkers” (0 cups per day) and “coffee drinkers” (>1 cups per day) to obtain 
overall results. Then the variable was classified into five categories; ‘0 cups per day’, ‘1-2 
cups per day’, ‘3-4 cups per day’, ‘5-6 cups per day’ and ‘>6 cups per day’. This variable was 
the main exposure of the present study, and the group who did not drink coffee (0 cups per 
day) was set as reference in the analysis. Moreover, the total coffee consumption variable 
was divided into “Boiled coffee” (coarsely ground coffee for brewing) and “Other coffee” 
(filtered coffee and other types of coffee) variables for separate analysis. The information of 
smoking status was drawn from the question “Do you/did you smoke daily?--Never/ Yes, 
previously/ Yes, now”. The baseline data of diabetes, the level of physical activities, history 
of cardiovascular diseases (heart attack/angina pectoris/stroke), dietary habits and illnesses 
in the family were also obtained from the Tromsø 4, 5, and 6 questionnaires. 
At the physical examination, body weight was measured in kilograms with 
participants wearing light clothes and no shoes and height was measured to the nearest 
centimeter. Body Mass Index (BMI) was calculated as weight divided by the square of height 
in meters (kg m2). Non-fasting blood samples were collected from an antecubital vein to 
measure serum total cholesterol, serum high-density cholesterol (HDL), and triglyceride. 
Blood samples were respite in room temperature for an hour, and then further 
measurements were conducted at the UNN, Department of Clinical Chemistry. Enzymatic 
colorimetric methods and commercially available reagents  were used to determine 
cholesterol and triglyceride levels (cholesterol: CHOD-PAP and triglycerides: GPO-PAP, 
Boeringer Mannhein). HDL cholesterol was computed after heparin-manganese chloride 
precipitation of low-density lipoproteins.  
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Information on cancer before study start and during follow-up was derived from the 
Cancer Registry of Norway, which has over 98% registration completeness (estimation for 
period 2001-2005) [106].  
 
3.3 Measurements (Outcome) 
 
Part I –Incident Venous Thromboembolism (VTE)– 
 
All incident VTE events during the follow-up period (1994-1995 to 31st December 
2012) were searched and derived from the hospital discharge diagnosis registry, the 
radiology procedure registry and the autopsy registry at the UNN. This hospital exclusively 
provides all the outpatient consultation, hospital care and relevant diagnostic radiology for 
VTE since UNN is the only hospital in the municipality. Outpatient clinic visits and 
hospitalization were included in the hospital discharge diagnosis registry. Not all VTE events 
were recorded in the hospital discharge diagnosis registry due to coding errors, therefore 
the radiology procedure registry was conducted to find potential cases of VTE events, which 
were missed from the diagnosis registry. The relevant International Classification of Disease 
(ICD) codes used in the search were 325, 415.1, 451, 452, 453, 671.3, 671.4, 671.9 for 
version 9 (1994-1998) and I26, I80, I81, I82, I67.6, O22.3, O22.5, 087.1, O87.3 for version 10 
(1999-2012) [107]. Trained personnel reviewed the diagnostic procedures of VTE performed 
at the Department of Radiology during the follow-up period and objectively confirmed the 
cases of VTE which were missing from the registry. Moreover, the autopsy diagnosis registry 
was searched through to identify the events of VTE. 
29 
The review of the medical records was undertaken by trained personnel, who were 
blinded to baseline characteristics of the patients, including coffee consumption habits. Each 
potential VTE event derived from the hospital discharge diagnosis registry or the radiology 
procedure registry was investigated and confirmed as a validated event if the following four 
conditions were fulfilled; 1) thrombosis confirmed through objective diagnostic procedure 
such as compression ultrasonography, venography, spiral computed tomography, perfusion-
ventilation scan, pulmonary angiography or autopsy; 2) the medical record indicated that a 
physician had diagnosed DVT or PE; 3) symptoms or clinical signs consistent with DVT or PE 
were evident; 4) the medical record indicated that the patient underwent treatment with 
anticoagulants (heparin, warfarin, or non-vitamin K anticoagulants), thrombolytic therapy or 
vascular surgery except when specific contradictions were noted. Unclear cases were taken 
to a discussion with a senior consultant with experience on VTE diagnosis (J. B. Hansen). Also 
if the death certificate of the cases collected from the autopsy registry indicated VTE as 
cause of death or the incidence of VTE had significantly contributed to death, the case was 
added as validated VTE event.  
All incident VTEs were categorized into either “provoked VTE” or “unprovoked VTE” 
for separate analysis. If one or more of the following factors were present at the time of 
diagnosis, the event was considered as “provoked VTE”: previous surgery or trauma within 
eight weeks, acute medical conditions like acute MI, ischemic stroke or major infectious 
disease, active cancer, immobilization (bed rest for three or more days, use of wheelchair, or 
more than four hours duration travel by car, train, boat or airplane within the previous 14 
days), or other possible provoking factors specified by a physician such as intravascular 




Part II –Recurrent VTE and Mortality– 
 
The information on recurrent VTE events and all-cause mortality for the study 
participants during the follow-up period was also recorded. The recurrent VTE events were 
collected and validated through the same procedures and criteria as used for incident VTE 
cases described earlier. The deaths of the participants were identified by using the unique 
national person identification number and derived from the Norwegian Population Registry.  
 
3.4 Statistical Analysis 
 
Statistical analyses were performed with STATA version 14.0 (Stata Corporation, 
College Station, TX, USA) and the significance level was set to 0.05. Baseline patient 
characteristics were calculated at the point when the participants attended the study survey 
for the first time (Tromsø 4 (1994-1995): 26,897 participants, Tromsø 5 (2001-2002): 849 
participants, Tromsø6 (2007-2008): 2,490 participants). The subjects who died (n=5,744) or 
moved (n=4,993) during the follow-up period were censored at the date of death or 
migration (Figure 4). The baseline data were given either in crude numbers with percentages 
or mean with standard deviation, and the distribution across coffee consumption categories 
is shown in Table 1. There were some variations in the number of subjects for each risk 
factor due to missing data, although the differences were not substantial in all covariates 
(<1% missing: except for physical activity: 5.7% missing).  
In order to avoid possible regression dilution bias [103], time-varying Cox 
proportional hazards regression analysis was used in the present study. The person-years at 
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risk for each participant were calculated in three separate time-windows; the period from 
Tromsø 4 to 5, from Tromsø 5 to 6, and from Tromsø 6 until the end of follow-up (Figure 3). 
Person-years were accrued from the date the subjects attended the survey to the date of 
VTE, death, migration or end of the time-window period. Crude incidence rates (IRs) were 
calculated as number of events divided by the person-years at risk, and given per 1,000 
person-years with 95% CIs. HRs were computed for each time-window and a weighted 
average of the separate time-windows was given as overall HR. Age was set as time scale so 
all the HRs were automatically adjusted for age. Furthermore, HRs were either adjusted for 
sex (Model 1) or multivariable (sex, BMI, smoking status (current smoker/ previous smoker/ 
never), physical activity (hard physical exercise for less than 1h/ 1-2h/ 3-4h/ none), self-
reported diabetes, history of CVD event, and cancer (cancer diagnosis within 10 years prior 
to enrollment) (Model 2).  
Separate analyses were carried out for provoked and unprovoked VTE outcomes. 
Analysis stratified by sex, age group under 70 years and type of consumed coffee (boiled or 
other) was also undertaken. Age stratification was conducted under the hypothesis of 
greater effects for young participants since age is a strong risk factor of VTE. Among 
participants who answered questions for both coffee types (n=27,707), 4,958 subjects 
answered that they consumed both boiled and other types of coffee daily. Those were 
excluded from the subgroup analysis separated by the different types of coffee intakes. The 
parallelism of log-log survivor function was evaluated to test the proportional hazard 
assumption. In addition, Schoenfeld residuals were tested for all the risk factors and the 
assumption was fulfilled for all the relevant variables when age was set as timescale.  
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As for the Part II analysis, risk of recurrent VTE events and all-cause mortality were 
analyzed. The subjects were followed from the date of VTE until the end of the study period, 
death (n=240), migration (n=13) or the date of recurrent VTE (n=77) for the recurrence 
analysis, whichever came first. Crude recurrence/mortality rates and HRs were calculated. 
Recurrence/mortality rates were obtained as number of events/deaths divided by the total 
person-years at risk and given in per 1,000 person-years with 95% CIs. HRs were computed 
using the same method as in the first analysis. HRs for the second VTE analysis were 
adjusted for the confounders in Model 1 and 2, and HRs for all-cause mortality were also 
adjusted for the same confounders except for cancer. The participants who did not have 







4.1 Part I: Coffee Consumption and Risk of Incident VTE 
 
Among 30,236 participants, there were 491 validated incident VTEs during 312,688 
person-years (median follow up time for the time-windows: 6.57 years). The baseline 
characteristics of the study participants are shown in Table 1. More than 89% of the 
participants (n=26,892) indicated that they drink at least one cup of coffee per day. The 
subjects who did not drink coffee (0 cups per day) were relatively younger (mean age 38.4 ± 
13.7) and experienced less cardiovascular events (2.5%) compared to the coffee drinkers. 
The level of cholesterol and number of current smokers significantly increased along with 
increase in daily coffee consumption. On the other hand, the level of hard physical activity 
decreased as coffee intake amount increased. The proportion of males and current smokers 
were high among excessive coffee drinkers (>6 cups per day) (59.7% and 58.6% 
respectively). In general, the participants who only drank boiled coffee (n=8,856) were older, 
had higher cholesterol, experienced more CVD events and had a higher proportion of 
current smokers compared to the participants who consumed other types of coffee 





Table 1: Baseline characteristics of the subjects measured at the time of enrollment* (n=30,236) 
 0 cups per day 1-2 cups per day 3-4 cups per day 5-6 cups per day >6 cups per day P for trend 
Subjects 3106 3430 7498 7922 8042 - 
Male 1218 (38.9) 1345 (38.8) 3178 (42.0) 3796 (47.6) 4834 (59.7) <0.001 
Age (years) 38.4 ± 13.7 46.4 ± 16.6 49.3 ± 15.8 48.1 ± 14.2 45.8 ± 12.4 <0.001 
BMI (kg m-2) 24.9 ± 4.2 25.1 ± 4.0 25.3 ± 3.9 25.4 ± 3.9 25.5 ± 3.9 <0.001 
Cholesterol (mM) 5.4 ± 1.2  5.8 ± 1.3 6.0 ± 1.3 6.1 ± 1.3 6.2 ± 1.3 <0.001 
Diabetes** 37 (1.2) 83 (2.4) 169 (2.2) 165 (2.1) 123 (1.5) 0.45 
History of CVD** 79 (2.5) 208 (6.0) 494 (6.5) 452 (5.7) 363 (4.5) 0.32 
Current smoker 557 (17.8) 574 (16.6) 1798 (23.8) 3120 (39.2) 3051 (58.6) <0.001 
Physical activity§** 1172 (37.4) 1095 (31.6) 2228 (29.5) 2281 (28.6) 2243 (27.7) <0.001 
Cancer҂ 38 (1.2) 73 (2.1) 159 (2.1) 157 (2.0) 121 (1.5) 0.69 
       
*Crude number (%) or means ± crude standard deviation **Self-reported. §Includes weekly average of hard physical 
activity (sweating/out of breath) for more than one hour. ҂Cancer diagnosis within 10 years from the study enrolment. 
 
 
The overall IR of incident VTE was 1.57 (95% CI, 1.44-1.72) per 1,000 person-years. In 
total, 193 cases (39.3%) were PE with or without concurrent DVT and 298 cases (60.7%) 
were DVT alone (Table 2). Among total VTE events, 202 cases (41.1%) occurred without any 
provoking factor(s) (unprovoked VTE). The most frequent risk factors among provoked VTE 
were active cancer (25.1%), immobility (20%), and acute medical conditions such as MI, 
stroke or major infectious disease within eight weeks prior to the event (13.4%). There were 
no differences in proportions of DVT, PE, unprovoked or provoked VTEs between sexes. The 
prevalence of risk factors were mostly comparable between gender groups though females 
had a slightly higher rate of surgery (16.1%) and trauma (8.9%) than male participants 
(14.3% and 6.7% respectively) (data not shown).  
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Table 2: Characteristics of VTE events (n=491) 
N (%) 
Male 224 (45.62) 
Deep vein thrombosis 298 (60.69) 
Pulmonary embolism 193 (39.31) 
Unprovoked VTE 202 (41.14) 
Clinical risk factors 
   Estrogens* 26 (5.3) 
   Pregnancy* 4 (0.81) 
   Heredity† 15 (3.06)  
   Other medical conditions‡ 110 (22.4) 
Provoking factors 
   Surgery 83 (16.9) 
   Trauma 35 (7.13) 
   Acute medical conditions 66 (13.44) 
   Cancer҂ 123 (25.05) 
   Immobility§ 98 (19.96) 
   Otherⱡ 26 (5.3) 
*Analysis only includes female. †Known/reported incidence of VTE in first-degree relative before the age of 60 years.
‡Comorbid condition such as COPD, MI, asthma, chronic infection, chronic obstructive pulmonary bowel disease or
myeloproliferative disorders within the previous year. ҂Active cancer at the time of VTE event. §Includes bed rest for 3 or 
more days, more than 4h duration travel by car, train, boat or airplane within last 14 days, or other immobilization. ⱡ Other 
possible provoking factors indicated in the medical record (e.g. intravascular catheter)
Table 3 contains IRs and HRs for total VTE events, provoked and unprovoked VTE, and 
analysis restricted to participants under the age of 70 (n=27,667). The coffee drinkers (>1 
cups per day) were associated with 37% decreased risk of incident VTE compared to non-
coffee drinkers (Model 2 HR 0.63, 95% CI 0.44-0.89). The crude IR was highest in the group 
who took 1-2 cups of coffee per day (2.15, 95% CI 1.73-2.66), however, the IRs were not 
adjusted for age or other confounding factors. For total VTE events, drinking 3-4 cups per 
day and 5-6 cups per day were associated with 42% and 41% reduced risk of the outcome 
events respectively (Model 2 HR 0.58, 95% CI 0.39-0.84 and HR 0.59, 95% CI 0.4-0.88) 
compared to the reference group (0 cups per day). Also drinking 1-2 cups per day was 
borderline associated with VTE events (Model 2 HR 0.67, 95% CI 0.44-1.01). The inverse 
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association to the risk of VTE slightly weakened for excessive coffee drinkers (>6 cups per 
day) (Model 2 HR 0.72, 95% CI 0.49-1.07).  
 
Table 3: Incidence rates (IRs) and hazard ratios (HRs) for VTE events by coffee consumption categories 
 Person-years Events IR¶(95% CI) M1 HR* (95% CI) M2 HR** (95% CI) 
Total VTE      
Coffee yes/no 312688.56 491 1.57 (1.44-1.72) 0.69 (0.49-0.97) 0.63 (0.44-0.89) 
      
0 cups per day 27382.74 36 1.31 (0.95-1.82) REF. REF. 
1-2 cups per day 39100.97 84 2.15 (1.73-2.66) 0.78 (0.52-1.15) 0.67 (0.44-1.01) 
3-4 cups per day 84570.55 151 1.79 (1.52-2.09) 0.65 (0.45-0.94) 0.58 (0.39-0.84) 
5-6 cups per day 83834.35 123 1.47 (1.23-1.75) 0.65 (0.45-0.95) 0.59 (0.40-0.88) 
>6 cups per day 77799.95 97 1.25 (1.02-1.52) 0.75 (0.51-1.1) 0.72 (0.49-1.07) 
P for trend    0.22 0.43 
      
Provoked VTE      
Coffee yes/no 312688.56 289 0.92 (0.82-1.04) 0.69 (0.80-1.08) 0.61 (0.39-0.96) 
      
0 cups per day 27382.74 21 0.77 (0.5-1.18) REF. REF. 
1-2 cups per day 39100.97 34 0.87 (0.62-1.22) 0.52 (0.30-0.90) 0.44 (0.25-0.79) 
3-4 cups per day 84570.55 97 1.15 (0.94-1.4) 0.70 (0.43-1.13) 0.59 (0.36-0.95) 
5-6 cups per day 83834.35 77 0.92 (0.73-1.15) 0.69 (0.42-1.12) 0.63 (0.38-1.03) 
>6 cups per day 77799.95 60 0.77 (0.6-0.99) 0.8 (0.48-1.33) 0.77 (0.46-1.28) 
P for trend    0.56 0.42 
      
Unprovoked VTE      
Coffee yes/no 312688.56 202 0.65 (0.56-0.74) 0.70 (0.41-1.19) 0.65 (0.37-1.13) 
      
0 cups per day 27382.74 15 0.55 (0.33-0.91) REF. REF. 
1-2 cups per day 39100.97 50 1.28 (1.97-1.69) 1.16 (0.64-2.10) 1.04 (0.56-1.93) 
3-4 cups per day 84570.55 54 0.64 (0.49-0.83) 0.58 (0.33-1.04) 0.56 (0.31-1.03) 
5-6 cups per day 83834.35 46 0.55 (0.41-0.73) 0.60 (0.33-1.07) 0.55 (0.29-1.01) 
>6 cups per day 77799.95 37 0.48 (0.34-0.66) 0.67 (0.37-1.23) 0.66 (0.35-1.25) 
P for trend    0.01 0.03 
      
 Total VTE § (aged <70)      
Coffee yes/no 278,372.13 292 1.05 (0.94-1.18) 0.62 (0.41-0.93) 0.64 (0.42-0.98) 
      
0 cups per day 25863.4 26 1.01 (0.68-1.48) REF. REF. 
1-2 cups per day 32310.71 35 1.08 (0.78-1.51) 0.61 (0.37-1.02) 0.63 (0.37-1.07) 
3-4 cups per day 70979.84 72 1.01 (0-81-1.28) 0.54 (0-34-0.85) 0.55 (0.32-0.88) 
5-6 cups per day 75385.81 80 1.06 (0.85-1.32) 0.60 (0.38-0.94) 0.62 (0.39-0.98) 
>6 cups per day 73832.36 79 1.07 (0.86-1.33) 0.73 (0.47-1.15) 0.79 (0.50-1.25) 
P for trend    0.91 0.88 
      
¶ Incidence rates (IRs) per 1000 person-years. *Model1 (M1): adjusted for age and sex. **Model 2 (M2): adjusted for age, 
sex, body mass index (BMI), smoking status, physical activity, diabetes, history of cardiovascular disease (CVD) and cancer. § 





For separate analysis on provoked and unprovoked VTE, coffee consumption was 
inversely associated with the outcome in both analyses (provoked: Model 2 HR 0.69, 95% CI 
0.39-0.96), unprovoked: Model 2 HR 0.65, 95% CI 0.37-1.13). For provoked VTE analysis, 1-2 
cups per day (Model 2 HR 0.44, 95% CI 0.25-0.79) and 3-4 cups per day (Model 2 HR 0.59, 
95% CI 0.36-0.95) were significantly associated with decreased VTE. As for analysis on 
unprovoked VTE, none of the categories revealed significance, however, overlapping 95% CIs 
indicated that the results were in line with the trend for provoked VTE results.  
The risk estimates for the analysis restricted to participants under 70 years of age were 
almost identical to the overall results (Table 3). Analysis adjusted by the use of estrogen also 
revealed a similar risk estimation trend (data not shown). Sex-stratified analysis revealed 
stronger inverse association to total VTE events for female participants (3-4 cups: Model 2 
HR 0.5, 95% CI 0.3-0.81 and 5-6 cups: Model 2 HR 0.53, 95% CI 0.32-0.88), nevertheless the 
differences between gender were not significant (S2 Table). The analysis according to 
different types of coffee (boiled/other) showed similar risk estimation to overall results, 
both for drinkers of boiled coffee and drinkers of other types of coffee. The associations 
were stronger in subjects who consumed other types of coffee (1-2 cups per day: Model 2 
HR 0.49, 95% CI 0.29-0.84, 3-4 cups per day: Model 2 HR 0.57, 95% CI 0.37-0.88, 5-6 cups per 
day: Model 2 HR 0.62, 95% CI 0.39-0.97) (S3 Table). Moreover, a separate analysis was 
conducted for participants aged under 70, although risk estimates were not altered (data 
not shown).  
 The results from Model 2 of our analysis were compared to the findings from Enga et 
al [99] (Table 4). Overall, the present study revealed a stronger association between coffee 
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consumption and VTE, and the risk estimates were lower in all categories compared to the 
previous study. Especially the HRs for 1-2 cups per day and 3-4 cups per day were notably 
lower in the time-varying analyses (1-2 cups: HR 0.78, 95% CI, 0.51-1.21 versus HR 0.67, 95% 
CI 0.44-1.01; 3-4 cups: HR 0.70, 95% CI 0.48-1.02 versus HR 0.58, 95% CI 0.39-0.84) (Table 4).  
 
Table 4: Comparison of results from the present study and Enga et al. 2011 
 Enga et al. 2011* Present study* 
0 cups per day REF. REF. 
1-2 cups per day 0.78 (0.51-1.21) 0.67 (0.44-1.01) 
3-4 cups per day 0.70 (0.48-1.02) 0.58 (0.39-0.84) 
5-6 cups per day 0.67 (0.45-0.97) 0.59 (0.40-0.88) 
>6 cups per day 0.85 (0.58-1.24) 0.72 (0.49-1.07) 
P for trend 0.71 0.43 
   
* HRs adjusted for age, sex, body mass index (BMI), smoking status, physical activity, diabetes,  
history of cardiovascular disease (CVD) and cancer. 
 The table is an adaptation of the results from the paper by Enga et al84 
 
 
4.2 Part II: Risk of VTE Recurrence 
 
Of the 491 participants who experienced VTE, 12 died on the day of the VTE (total subjects 
n=479, total person-years=2,270) and 76 developed VTE for the second time during the 
follow-up period (mean time from the first VTE incident: 5.4 ± 4.6 years). The characteristics 
of recurrent VTEs are given in Table 5. Mean age at the time of recurrence was 65 ±12.2 
years but the range varied from 27 to 85 years. There were 46 cases (60%) of DVT and 30 
cases (40%) had concurrent PE. Out of these, 45% (34 cases) were unprovoked VTE and 21% 




Table 5: Characteristics of recurrent events (n=76) 
 N (%) 
Male 39 (51) 
Age* 65 ± 12.2 
Deep vein thrombosis 46 (60) 
Pulmonary embolism 30 (40) 
Unprovoked VTE 34 (45) 
Cancer** 16 (21) 
Time from 1st VTE* 5.4 ± 4.6 
  
*Mean (year) ± crude standard deviation. **Active cancer at the time of VTE recurrence 
 
Overall recurrence rate was 35.0 (95% CI 28.0-43.8) per 1,000 person-years. The highest 
recurrence rate was 69.6 (95% CI 38.6-125.7) for the coffee abstainers (0 cups per day). The 
HRs adjusted for possible confounders (age, sex, BMI, smoking status, physical activity, 
diabetes, CVD and cancer) for coffee drinkers was 0.34 (95% CI 0.17-0.67), indicating a 66% 
lower risk of recurrent VTE for participants who drink more than one cup of coffee daily. All 
four categories (1-2 cups, 3-4 cups, 5-6 cups and >6 cups per day) were significantly 
associated with the decreased risk of recurrent VTE; 1-2 cups per day (Model 2 HR 0.08, 95% 
CI 0.02-0.38), 3-4 cups per day (Model 2 HR 0.38, 95% CI 0.17-0.84), 5-6 cups per day (Model 
2 HR 0.36, 95% CI 0.16-0.82) and >6 cups per day (Model 2 HR 0.43, 95% CI 0.19-0.94) (Table 
6). Further analysis was conducted excluding the cancer-related VTE patients (n=123), 





Table 6: Incidence rates (IRs) and hazard ratios (HRs) of recurrent VTE (n=479) 
 Person-years Events IR (95% CI) ¶ M1 HR* (95% CI) M2 HR** (95% CI) 
Total 2nd VTE     
Coffee yes/no 2171.0 76 35.0 (28.0-43.8) 0.38 (0.20-0.75) 0.34 (0.17-0.67) 
      
0 cups per day 158.0 11 69.6 (38.6-125.7) REF. REF. 
1-2 cups per day 341.8 3 8.8 (2.8-27.2) 0.10 (0.27-0.37) 0.08 (0.02-0.38) 
3-4 cups per day 603.3 25 41.4 (28.0-61.3) 0.50 (0.23-1.00) 0.38 (0.17-0.84) 
5-6 cups per day 481.7 18 37.4 (23.5-59.3) 0.43 (0.20-0.94) 0.36 (0.16-0.82) 
>6 cups per day 586.2 19 32.4 (20.6-50.8) 0.44 (0.20-0.95) 0.43 (0.19-0.94) 
      
¶Crude IRs per 1,000 person-years. *Model1 (M1): adjusted for age and sex. **Model 2 (M2): adjusted for age, sex, body 
mass index (BMI), smoking status, physical activity, diabetes, history of cardiovascular disease (CVD) and cancer. 
 
 
4.3 Part II: All-cause Mortality after VTE 
 
During a mean follow-up of 4.9 years (range from 1 day to 18.1 years), 240 participants 
died. Twelve patients who died on the day of the VTE event were given one day of follow-up 
period and included in the analysis. The overall crude mortality rate was 99.1 (95% CI 87.3-
112.4) per 1,000 person-years and the highest was among participants who drink 1-2 cups of 
coffee per day (125.5, 95% CI 93.3-168.6) (Table 7). The mortality rate was slightly higher for 
female (101.8, 95% CI 85.8-120.8) than male participants (95.9, 95% CI 79.4-115.8) (data not 
shown). The proportional HRs decreased as coffee consumption increased and the estimated 
risk was smallest for the excessive coffee drinkers (>6 cups per day) (Model 2 HR 0.63, 95% 
CI 0.35-1.13). However, the risk estimations were not significant in all categories. The 
subgroup analysis only including the non-cancer related VTE cases (n=368) revealed a similar 





Table 7: All-cause mortality rate (MR) and HRs after first VTE incident (n=491) 
 Person-years Events MR (95% CI) ¶ M1 HR* (95% CI) M2 HR§ (95% CI) 
All-cause mortality     
Coffee yes/no 2422.8 240 99.1 (87.3-112.4) 0.88 (0.74-1.25) 0.82 (0.50-1.34) 
      
0 cups per day 198.5 18 90.7 (57.1-143.9) REF. REF. 
1-2 cups per day 350.7 44 125.5 (93.3-168.6) 1.01 (0.57-1.78) 1.00 (0.56-1.80) 
3-4 cups per day 686.5 78 113.6 (91.0-141.8) 0.92 (0.54-1.56) 0.80 (0.46-1.38) 
5-6 cups per day 559.6 60 107.2 (83.2-138.1) 0.89 (0.52-1.53) 0.92 (0.53-1.58) 
>6 cups per day 627.5 40 63.7 (46.8-86.9) 0.71 (0.40-1.26) 0.63 (0.35-1.13) 
      
All-cause mortality ҂ (non-cancer related VTE)    
Coffee yes/no 2251.6 129 61.7 (52.3-72.9) 0.82 (0.43-1.60) 0.73 (0.38-1.43) 
      
0 cups per day 175.7 10 56.9 (30.6-105.7) REF. REF. 
1-2 cups per day 316.0 32 101.2 (71.6-143.2) 1.14 (0.57-2.39) 1.10 (0.51-2.35) 
3-4 cups per day 628.1 49 78.0 (59.0-103.2) 0.89 (0.44-1.80) 0.79 (0.39-1.63) 
5-6 cups per day 532.6 27 50.7 (34.8-73.9) 0.65 (0.31-1.37) 0.55 (0.25-1.18) 
>6 cups per day 599.2 21 35.0 (22.8-53.7) 0.74 (0.34-1.61) 0.63 (0.29-1.39) 
      
¶Crude all-cause mortality rate (MR) per 1,000 person-years. *Model 1 (M1): Adjusted for age and sex. § Adjusted for age, 
sex, body mass index (BMI), smoking status, physical activity, diabetes, and history of cardiovascular disease (CVD) 









5.1 Overall Results 
 
The results of the present study indicated an inverse association between coffee 
consumption and the risk of incident VTE, recurrent VTE and all-cause mortality after a VTE 
event. Daily intake of coffee was associated with a 37% lower risk of incident VTE compared 
to coffee abstainers after adjusting with multiple confounding factors. The association was 
particularly strong for the group who consumed 3-4 cups and 5-6 cups of coffee daily. The 
inverse association was slightly weakened for the excessive coffee drinkers (>6 cups per 
day), suggesting a possible U-shaped association between VTE and coffee drinking habits. 
Subgroup analyses of unprovoked/provoked VTE, different types of coffee, gender and age 
(>70) were all corresponding to the main results. Among those with a first VTE, the 
recurrence rate was 66% lower in those who consumed at least one cup of coffee daily. The 
recurrence rate was lowest among the participants with low coffee consumption (1-2 cups), 
but the risk estimations were low across all coffee intake categories. Moreover, the coffee 
drinkers had an 18% reduced risk of all-cause death following a first VTE. After stratifying for 
non-cancer related VTE patients, the inverse association was strongest for the subjects who 
drank 5-6 cups per day (45% reduction), revealing a possible J-shaped association. 
 






The findings of the Part I analysis are in agreement with the results of three previous 
observational studies and a meta-analysis pooling the three [81, 99-101]. A large case-
control study (MEGA study) conducted to explore the risk factors of VTE showed a 25% 
lower risk of VTE for coffee consumers when matched against the partner controls (OR 0.75, 
95% CI 0.55-1.04), regardless of the amount of coffee consumed daily [100]. Also the 
prospective cohort study (IWHS) with over 37,000 female participants revealed an inverse 
association between VTE and consumption of 28 to <42 cups of coffee per week 
(corresponding to 4-6 cups per day) (HR 0.85, 95% CI 0.71-1.01), which is in accordance with 
our findings [81]. However, the authors of IWHS reported the attenuated risk estimates after 
further adjustment with BMI and diabetes. The present study included both genders and the 
analysis were adjusted for multiple factors including BMI and self-reported diabetes status.  
Yet the inverse association with VTE remained strong for moderate coffee consumption (3-6 
cups daily). A meta-analysis including all three observational studies demonstrated no 
significant association between overall coffee intake and VTE (cumulative RR 0.97, 95% CI 
0.88-1.08), while a 25% risk reduction was revealed for high-amount coffee drinkers (≥5 cups 
daily: RR 0.75, 95% CI 0.67-0.85). The inter-study heterogeneity was high (I-squared 78%, 
P<0.001), thus the pooled results need to be assessed with caution, nonetheless the overall 
trends were still in line with our risk estimations. 
The previous study based on the participants of the Tromsø 4 survey reported a 30%  
and 33% decreased risk of VTE for participants who consumed 3-4 cups (HR 0.70, 95% CI, 
0.48-1.02) and 5-6 cups of coffee daily (HR 0.67, 95%CI 0.45-0.97) [99]. As mentioned in the 
introduction, the present study used time-varying analysis to minimize the influence of 
possible regression dilution bias which was not addressed in the previous Tromsø 4 study 
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[99] and IWHS [81]. In our study, the information about the coffee consumption habit was 
measured at each survey and the classification was updated a maximum of three times 
during the follow-up period. Also, the present study used the same confounding variables as 
the Tromsø 4 study [99] to adjust the models for comparison purposes.  
The number of total subjects increased from 26,755 in the previous study to 30,236, 
due to the inclusion of participants from Tromsø 5 and 6. The prevalence of baseline 
characteristics across the coffee consumption categories was almost identical in both 
studies, indicating that the results can be compared. The present study demonstrated lower 
risk estimations across all coffee intake categories and the associations were stronger 
compared to the previous study. Especially the multivariable adjusted HRs dropped 
noticeably for the groups with 1-2 cups and 3-4 cups of daily coffee consumption (1-2 cups: 
HR 0.78 to 0.67, 3-4 cups: HR 0.70 to 0.58), which indicates that the results of the previous 
study were affected by regression dilution bias to some extent. Hence, the misclassification 
might have altered the findings of the previous study slightly. However, the 95% CIs of the 
risk estimations were overlapping in both studies, thus the differences are not significant. It 
can be assumed that the exposure variable remained relatively consistent throughout the 
study period, meaning one does not change one’s coffee consumption habit predominantly 
over time. The findings of the present study suggest that the regression dilution bias was not 






Recurrent VTE  
 
To the best of our knowledge, no studies have investigated the association between coffee 
intake and the risk of VTE recurrence. Our study revealed a 66% lower risk of recurrence (HR 
0.34, 95% CI 0.17-0.67) for coffee drinkers compared to patients who do not drink coffee. 
The index event bias can be a limitation in recurrence studies when the population was 
selected on the basis of the occurrence of the index event [108-110]. However, the recurrent 
analysis of the present study indicated extensive decrease in risk of VTE recurrence among 
coffee drinkers, suggesting a limited chance of the findings being affected by the index event 
bias.  
The strong association could potentially be explained by uneven prevalence of other 
diseases among coffee abstainers. We conducted a further analysis excluding cancer-related 
VTE patients since cancer is a strong predicting factor of VTE recurrence [18, 20, 111]. 
However, the risk estimates were not greatly altered, indicating that the high prevalence of 
cancer among non-coffee drinkers was not the explanation of the inverse association 
between coffee consumption and the risk of recurrent VTE. There is a possibility that the 
study was affected by unmeasured confounding factors which are still unidentified and yet 
have strong influence on risk of VTE recurrence, or coffee drinking truly has a protective 




The analysis revealed an inverse association between coffee consumption and all-cause 
mortality after a VTE event (HR 0.82, 95% CI 0.5-1.34 for habitual coffee drinkers), with very 
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high-amount coffee consumers (>6 cups per day) having the lowest risk estimates (HR 0.63, 
95% CI 0.35-1.13). While our study is believed to be the first to investigate the relation 
between coffee consumption and mortality after a incident VTE, a large number of studies 
can be found on coffee intake and total mortality on other populations. Most of these 
studies revealed a U-shaped association between coffee intake and mortality [112-117]. A 
recent paper from the HAPIEE study (Health, Alcohol and Psychological  factors in Eastern 
Europe) reported that consuming 3-4 cups of coffee per day was associated with 17% and 
37% lower risk of death for men and women respectively (men: HR 0.83, 95 % CI 0.71-0.99, 
women: HR 0.63, 95 % CI 0.47-0.84), although further intake was not significantly associated 
with all-cause mortality [112]. Similarly, a large Danish observational study with a total of 
95,366 individuals and 5,422 deaths during a median of six years study period revealed the 
lowest mortality rate for subjects with a moderate coffee intake compared to coffee 
abstainers, and the overall association was U-shaped [114]. A meta-analysis of 20 
prospective cohorts also concluded that there was an inverse association between coffee 
intake and the risk of death (pooled RR 0.86, 95 % CI 0.80-0.92), but not necessarily a dose-
response relationship, since high coffee consumption (≤5-9 cups/day) did not reduce the risk 
of death further compared to moderate consumption [116]. Our study also illustrated the U-
shaped risk estimates when cancer-related VTE patients were excluded from the analysis.  
 
5.3 Underlying Mechanisms  
 
Coffee is a complex mixture of active components such as caffeine, polyphenols, aminoacids 
and minerals, which can affect human health [117, 118]. The amount of intake and 
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metabolites of these components depend on the coffee type, methods of brewing, and 
serving size, which all influence the beneficial effect of coffee on health [117]. The complete 
mechanisms of how coffee acts beneficially in reducing the risk of VTE are still unclear, but 
several hypotheses can be outlined from previous studies [100, 119].  
 
Hemostatic Factors and Fibrinolytic Activity 
 
Plasma levels of vWF and FVIII are associated with the risk of VTE [120, 121]. Roach et al 
suggested in their study that the inverse association between coffee consumption and VTE 
might be mediated through levels of vWF and FVIII which were found to be lower among 
coffee drinkers compared to non-coffee drinkers [100]. Moreover, the inverse association of 
coffee and VTE was curtailed when procoagulant factors (fibrinogen, vWF, and FVIII) were 
added to the multivariable model [100]. No association was shown between coffee intake 
and levels of protein C, protein S, and antithrombin. However, another study showed that 
coffee extracts had an anti-thrombin activity in humans independent from caffeine, 
particularly in some types of coffee beans (Blue Mountain, Yunnan and Kilimanjaro) [122]. 
On the other hand, a small randomized controlled trial conducted in the Netherlands 
revealed no difference in the levels of fibrinogen and FVIII activity after nine weeks of coffee 
consumption [123].  
Decreased fibrinolytic activity might be associated with the increased risk of 
developing VTE [124-126]. There are several studies which investigated the effect of coffee 
on fibrinolytic activity, yet the findings are diverse. An experiment on the short-term effect 
of coffee demonstrated increased fibrinolytic activity and shortened clot lysis time for ten 
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out of 12 coffee drinkers [127], indicating possible benefits of coffee consumption on the 
fibrinolytic system. On the other hand, Roach et al found no difference in fibrinolytic clot 
lysis time for coffee drinkers and coffee abstainers [100]. In contrast to the above two, a 
Greek study found an increased level of plasminogen activator inhibitor 1 (PAI-1) and an 
impaired fibrinolysis system among heavy coffee drinkers with hypertension and a smoking 
habit [128]. The findings of our study also demonstrated attenuated association to VTE 
events among excessive coffee drinkers, and therefore the results are not necessarily 
conflicting. Overall, the amount of evidence on this topic is limited, and thus further 
investigations are necessary to confirm the effect of coffee on plasma hemostatic levels and 




Platelets are involved in the formation of both arterial and venous thrombosis [129], thus 
platelet hyperaggregability could be related to increased risk of VTE [130]. The potential 
influence of coffee on platelet aggregation might play another role in explaining the 
association between coffee intake and the risk of VTE. A crossover study conducted on ten 
healthy subjects showed decreased platelet aggregation and increased phenolic acid platelet 
concentration in coffee drinking subjects [131]. Similar findings were reported from older 
experiments on humans and rabbits, showing that intravenous administration of coffee 
extracts had anti-aggregatory effects in vitro [132]. Natella et al suggested that the 
interaction of coffee polyphenols with intracellular networks relating to platelet aggregation 
might play a role [131]. Nardini et al demonstrated in their systematic review that the 
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supplementation of phenolic-rich foods such as coffee, grape juice or green tea had an anti-
platelet aggregation effect in the majority of cases [133]. However, not all studies agreed 
with the findings above, for example, a report from Polaguruto et al revealed no influence 
on clotting time or plasma prostacyclin concentrations for coffee consumers [134]. 
Moreover, an older study from 1988 showed a significant increase in platelet reactivity one 
hour after administration of 100 mg of caffeine, which corresponds to one cup of coffee 
[135]. 
 
Polyphenols and Endothelial Function 
 
Another possible explanation could be the favorable effect of polyphenols on endothelial 
functions. The most abundant polyphenol in coffee is 5-caffeoylquinic acid, also called 
chlorogenic acid (CGA) [136], which was proven to have an acute improvement effect on 
endothelial function in a recent crossover study with 16 healthy men and women. CGA was 
given in two doses, 450 mg and 900 mg per day (equivalent to four and eight cups of coffee), 
and both groups were associated with ameliorated continuous mean flow-mediated dilation 
(FMD) response [137]. The findings are in accordance with several studies that investigated 
the effect of coffee polyphenols on endothelial function in healthy male participants [138-
140]. Another study conducted on healthy and diabetic women  reported that both 
caffeinated and decaffeinated coffee was inversely associated with inflammation markers 
and endothelial dysfunction [141]. On the other hand, two studies indicated that caffeinated 
coffee induced an unfavorable effects on endothelial function in healthy male subjects while 
decaffeinated coffee had no such effect [142, 143].  The discussion is still ongoing whether 
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the unfavorable effect was induced by caffeine or antioxidants [144]. Nonetheless, as Roach 
et al commented in their paper, endothelium and platelets are closely interrelated with vWF 
and thrombin formation [145], and it is therefore plausible that the effect of polyphenols on 
endothelial function is one of the mechanisms underlying the association between coffee 




A number of studies have revealed that caffeine is associated with an acute increase of 
blood pressure, endothelial dysfunction, inflammation, impaired glucose tolerance and 
inhibition of insulin activity [143, 146, 147]. However, it has also been reported that chronic 
consumption of coffee builds tolerance to caffeine (i.e. acute negative effects appear only 
for the participants who do not regularly drink coffee) [143, 147]. Therefore, the favorable 
effects of multiple compounds included in coffee might outweigh the acute negative effect 




The notable strengths of the present study are the large sample size of participants recruited 
from the same residential area and the high attendance rate (>65% in all three surveys). The 
inhabitants of Tromsø are mostly Caucasians and have relatively high standards of education 
and lifestyle factors. The incidence rate of VTE was also in accordance with those reported in 
other Western countries [11, 43]. Therefore it can be assumed that the study has relatively 
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high external validity for a Western population. Prospective study design, long follow-up 
period and repeated measurements of the exposure variables are further strong advantages 
of the present study. The VTE information was obtained from a single hospital, which is the 
only institute in the entire municipality, thus the completeness of the VTE registration in the 
studied area is presumably high. 
 




Owing to the fact that the present study is an observational cohort study, the possibility of 
residual confounding cannot be eliminated. It can be seen from the patient characteristics of 
the present study that the participants who consumed high amounts of coffee had relatively 
unhealthy lifestyle habits such as smoking or being less involved in a regular physical activity. 
However, adding those factors into the model along with the known risk factors of VTE such 
as age, sex, BMI, cancer and pre-conditional cardiovascular diseases did not attenuate the 
results. There is also a possibility that the status of coffee abstainers was particularly linked 
to poor health. For example, persons who experienced a disease might have refrained from 
coffee drinking in an attempt to achieve a healthy lifestyle. Therefore, the findings might be 
biased by underlying diseases or poor health conditions among participants who do not 
drink coffee. However, coffee abstainers of the present study were younger and had lower 
prevalence of diseases like diabetes, history of cardiovascular events, and cancer. They also 
had lower levels of cholesterol and BMI and more participants were dedicated to hard 
physical exercise compared to coffee consumers. Despite the relatively healthier conditions 
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among coffee abstainers, a significant inverse associations remained in the multivariable 
adjusted models, indicating that the findings of the present study are unlikely to be 
explained by unmeasured residual confounding.   
 
Measurements of the Exposure and Sample Size 
 
A possible weakness regarding the methodology is the fact that our main exposure variable, 
coffee consumption was obtained through questionnaires. Some measurement error and 
misclassification cannot be avoided in self-reported measurements. However, a validation 
study in German adults showed a high correlation between coffee consumption reported in 
a food frequency questionnaire (FFQ) and a 24 hour telephone recall (r=0.78) [148]. Hence, 
questionnaires are a relatively reliable method to obtain coffee intake information.  
Moreover, the probability of attaining the incorrect measurements was equal with 
regard to participants who experienced VTE and those who did not. The coffee consumption 
habit was measured at the study enrollment, thus the reported coffee intake amount was 
not influenced by the occurrence of the outcome event. This is called non-differential 
misclassification and can bias the results towards null [149]. The effect of regression dilution 
bias also needs to be taken into consideration for the Part II analysis, since the coffee intake 
information before the first VTE event was used in that analysis and was not updated until 
the end of follow-up. However, a strong association was revealed in both Part I and Part II 
analyses, and therefore the effect of misclassification and regression dilution bias on our 
findings is most likely minimal.  
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The present study lacks information about precise measurement of the coffee intake 
per day (size of the coffee cup), use of milk, sugar and/or other additional toppings, types of 
coffee other than boiled (e.g. espresso, instant coffee, cappuccino) and the amount of 
caffeine consumed with coffee. Moreover, we did not adjust for daily caloric intake in the 
present study. However, the previous Tromsø 4 study revealed almost no difference in 
results after adjusting with caloric intake for the subgroup aged 25-69 years [99]. Therefore, 
the caloric intake with or without coffee probably did not confound our findings. 
The limited statistical power of the analysis of recurrence and mortality also needs to 
be noted. For example, only three events occurred among the patients who consumed 1-2 
cups of coffee daily during the entire follow-up period in recurrent VTE analysis. Both 
recurrence and mortality analyses were not stratified by further categories like sex, age, 
provoked/unprovoked VTEs or types of consumed coffee due to the small number of 
incidents. Nevertheless, strong inverse associations were indicated for most of the coffee 
consumption categories, and the risk estimation trend was similar to the Part I analysis.  
Finally, information about a previous history of VTE prior to the study enrolment 
might be lacking for some of the study participants. Thus, some subjects who experienced an 
VTE event in the past and therefore needed to be excluded from the study might still be 
included in our analyses. However, considering the size of study population, the possible 






Overall, coffee consumption was associated with a 37% decreased risk of incident VTE. 
Moreover, coffee consumers had a 66% lower risk of recurrence and an 18% decreased risk 
of all-cause mortality after an event of VTE compared to coffee abstainers. The association 
was U-shaped in all analyses, suggesting that a moderate daily coffee intake (3-6 cups) may 
be beneficial. The study used time-varying analysis to minimize the regression dilution bias. 
The risk estimates were lower in present findings compared to a previous study using 
conventional analyses, nonetheless the differences were not significant. Because data on 
this topic are scarce, especially on recurrence and mortality after an incident VTE, further 
experimental and epidemiological studies are necessary in order to affirm the effect of 
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S1 Table: Baseline characteristics (Boiled/Other coffee)  
Boiled coffee: n=11,935 0 cups per day 1-2 cups per day 3-4 cups per day 5-6 cups per day >6 cups per day 
Subjects 3079 1117 2294 2647 2798 
Male 1201 (39.0) 456 (40.8) 905 (39.5) 1206 (45.6) 1646 (58.8) 
Age (years) 38.3 ± 13.6 49.0 ± 18.4 55.0 ± 17.4 51.9 ± 15.9 48.1 ± 13.8 
Cholesterol (mM) 5.4 ± 1.2  6.0 ± 1.4 6.4 ± 1.4 6.4 ± 1.3 6.4 ± 1.3 
History of CVD 76 (2.5) 90 (8.1) 264 (11.5) 209 (7.9) 152 (5.4) 
Current smoker 541 (17.6) 239 (21.4) 606 (26.4) 1162 (43.9) 1855 (66.3) 
Other coffee: n=13,893      
Subjects 3079 1776 3306 3173 2559 
Male 1201 (39.0) 670 (37.7) 1375 (41.6) 1542 (48.6) 1548 (60.5) 
Age (years) 38.3 ± 13.6  45.3 ± 15.7 47.6 ± 14.5 47.1 ± 13.0 45.8 ± 11.5 
Cholesterol (mM) 5.4 ± 1.2 5.7 ± 1.2 5.8 ± 1.3 5.9 ± 1.2 6.0 ± 1.2 
History of CVD 76 (2.5) 95 (5.4) 161 (4.9) 170 (5.4) 126 (4.9) 
Current smoker 541 (17.6) 243 (13.7) 744 (22.6) 1150 (36.3) 1412 (55.2) 




S2 Table: Sex-stratified analysis for VTE events by coffee consumption categories 
 Person-years Events M1 HR* (95% CI) M2 HR** (95% CI) 
Female (n=15,589)     
Coffee yes/no 166727.25 267 0.69 (0.44-1.07) 0.59 (0.38-0.93) 
     
0 cups per day 16775.13          22 REF. REF. 
1-2 cups per day 24243.02          58 0.84 (0.51-1.39) 0.73 (0.43-1.22) 
3-4 cups per day 50219.77          84 0.59 (0.37-0.96) 0.5 (0.30-0.81) 
5-6 cups per day 43954.77          62 0.63 (0.38-1.03) 0.53 (0.32-0.88) 
>6 cups per day 31534.56          41 0.82 (0.49-1.39) 0.77 (0.46-1.32) 
P for trend   0.31 0.33 
     
Male (n=14,205)     
Coffee yes/no 145961.31 224 0.71 (0.41-1.23) 0.71 (0.40-1.25) 
     
0 cups per day 10607.61          14 REF. REF. 
1-2 cups per day 14857.95          26 067 (0.35-1.28) 0.57 (0.28-1.16) 
3-4 cups per day 34350.78          67 0.76 (0.43-1.36) 0.74 (0.40-1.36) 
5-6 cups per day 39879.58          61 0.69 (0.38-1.23) 0.71 (0.39-1.30) 
>6 cups per day 46265.39          56 0.71 (0.40-1.29) 0.74 (0.40-1.36) 
P for trend   0.51 0.95 
     
*Model1 (M1): adjusted for age. **Model 2 (M2): adjusted for age, body mass index (BMI), smoking status, 




S3 Table: Analysis according to boiled or other types of coffee consumption categories  
 Person-years Events M1 HR* (95% CI) M2 HR** (95% CI) 
Boiled coffee     
Coffee yes/no 101948.21 170 0.69 (0.47-1.01) 0.67 (0.45-1.00) 
     
0 cups per day 26783.42 35 REF. REF. 
1-2 cups per day 9848.43 25 0.92 (0.54-1.55) 0.91 (0.53-1.55) 
3-4 cups per day 19791.37          48 0.72 (0.46-1.14) 0.68 (0.42-1.09) 
5-6 cups per day 22362.69          33 0.56 (0.34-0.90) 0.55 (0.33-0.89) 
>6 cups per day 23162.31 29 0.67 (0.41-1.11) 0.67 (0.40-1.11) 
P for trend   0.02 0.03 
     
Other coffee     
Coffee yes/no 147524.52         216 0.66 (0.46-0.96) 0.59 (0.40-0.86) 
     
0 cups per day 26783.42       35 REF. REF. 
1-2 cups per day 20308.81          33 0.65 (0.40-1.05) 0.49 (0.29-0.84) 
3-4 cups per day 39090.21          65 0.65 (0.42-0.98) 0.57 (0.37-0.88) 
5-6 cups per day 35188.36          53 0.69 (0.45-1.07) 0.62 (0.39-0.97) 
>6 cups per day 26153.71          30 0.67 (0.41-1.11) 0.67 (0.40-1.11) 
P for trend   0.23 0.33 
     
*Model1 (M1): adjusted for age and sex. **Model 2 (M2): adjusted for age, sex, body mass index (BMI), smoking status, 
physical activity, diabetes, history of cardiovascular disease (CVD) and cancer. 
 


